Release Date: 02/09/15 09:02 Summary: University of Adelaide to confirm commercial viability Price Sensitive: Yes Download Document 69.79KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%